Search
  • EpiEndo IR

EpiEndo Wins #1 Place in Biotech & Pharmaceuticals, at the European Innovation Council Investor Day

REYKJAVIK, ICELAND – 28 May 2021 – EpiEndo Pharmaceuticals (www.epiendo.com), a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, is announced as the winner of the Biotech & Pharmaceuticals category, at the European Innovation Council Investor Day on Health 2021.


The EIC Investor Day on Health, which took place on 18-19 May 2021, focused on innovations in the field of biotech, pharmaceuticals, medtech and ehealth. In total 25 EIC beneficiaries had the opportunity to pitch in front of 17 top-tier investors in the health-sector.

The EIC Investor Day on Health, which took place on 18-19 May 2021, focused on innovations in the field of biotech, pharmaceuticals, medtech and ehealth. In total 25 EIC beneficiaries had the opportunity to pitch in front of 17 top-tier investors in the health-sector.

“Receiving the EUR 2,7m commitment has provided strong support for EpiEndo at a critical juncture and has enabled us to move into Phase 1 clinical trials, a very important step forward”
Maria Bech, CEO

“Our therapeutic strategy is to improve the conditions of patients by reducing inflammation through enhancing the integrity of the airway epithelial barrier,” commented CEO, Maria Bech. Finnur Einarsson further explained: “After decades of research and validation, there is now widespread and growing acceptance of the critical importance of integrity of the epithelium, the layer of cells that make up the inner surface of the lung, as well as the skin and gut. If this is disrupted and leaky, it drives inflammation. EpiEndo’s highly differentiated approach is to addresses this underlying causal pathophysiology”. Commenting on the EIC, Finnur mentioned “This is our second BAS event, and we are delighted to emerge as a category winner. Pitching to the assembled VCs is a challenge and we have also found it to be a great networking opportunity”. Lastly, Maria shared more about the significant investment by the EIC fund, “Receiving the EUR 2,7m commitment has provided strong support for EpiEndo at a critical juncture and has enabled us to move into Phase 1 clinical trials, a very important step forward”.



The EU promotes a vision of a healthier European Union 2021-2027. The European Commission (EC) is investing in research, technology, and innovation to develop solutions that will help overcome challenges in the field of health such as, ageing, chronic diseases, or even external environmental factors i.e., antimicrobial resistance. With the EIC Investor Day on Health the EIC offered 25 of Europe’s most innovative SMEs the opportunity to pitch their health-related innovation to close to 20 investors.


###


About EpiEndo Pharmaceuticals (www.epiendo.com)

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflammation.


EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs.

EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases.


For more information, please visit www.epiendo.com


About the European Innovation Council Fund

Established in June 2020, the European Innovation Council Fund (EIC Fund) is a breakthrough initiative of the European Commission with a mission to make direct equity and quasi-equity investments (between €500,000 and €15 million) in European high impact and deep tech start-ups and scale ups. The EIC Fund provides patient capital and invests in companies from any sector, across all EU countries, and also countries associated with Horizon 2020.


The Fund pays particular attention to empower and support female founders as well as contributing to reduce the innovation divide among EU countries.

The EIC Fund aims to fill a critical financing gap and its main purpose is not to maximise financial investment returns, but to have a high impact by assisting disruptive technology companies with their growth. Its objective is to crowd in market players, further sharing risks by building a large network of capital providers and strategic partners suitable for co-investments and follow on funding.


For more information, please visit https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2530


Contact

Maria Bech

CEO

Email: maria.bech@epiendo.com

Tel.: [+354] 454 0090


Forward-Looking Statements

This press release may contain certain forward-looking statements concerning the financial condition, results of operations and businesses of the Company. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this presentation. The information in this presentation is subject to updating, completion, revision, further verification, and amendment without notice and the Company does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

25 views0 comments